Silver Springs, Maryland — In a groundbreaking step towards revolutionizing weight management, the Food and Drug Administration (FDA) has given the green light to a new glucose monitoring system from Signos, the first of its kind specifically designed for weight loss. This approval opens up new avenues for individuals looking to effectively manage their weight, offering an alternative to traditional medications and surgeries.

Unlike popular anti-obesity medications, which are often limited to patients with a specific body mass index or those diagnosed with obesity, Signos aims to broaden accessibility. With its innovative system, any consumer can purchase a membership to harness AI-driven insights paired with continuous glucose monitoring technology. This system uses over-the-counter glucose monitors from Dexcom, enabling users to receive personalized, real-time feedback concerning their dietary habits and activities.

Signos co-founder and CEO Sharam Fouladgar-Mercer emphasized the inclusive nature of their solution. “Now, anyone can benefit from this technology regardless of their weight. Whether someone needs to shed a few pounds or significantly more, we are committed to supporting them throughout their weight loss journey,” he stated.

The obesity crisis in the United States is a pressing issue, impacting nearly 74% of adults, according to recent data. The financial toll of obesity-related conditions on the healthcare system exceeds $170 billion annually. With this innovative approach, Signos aims to alleviate some of that burden, making a notable difference in public health.

Prospective members of Signos can select from plans ranging from three to six months, costing $139 and $129, respectively. Upon enrollment, users are provided with all necessary glucose monitoring devices for the duration of their chosen plan. While health insurance coverage remains non-existent for this specific use, the program is significantly more affordable than some conventional treatments, which can reach up to $1,000 monthly in the U.S.

Signos is also actively collaborating with insurance companies and employers to broaden coverage for its service, anticipating rapid adaptation in response to a growing interest in effective weight management solutions. The platform is designed to complement other weight loss methods, such as GLP-1 medications or bariatric surgery, allowing for a comprehensive approach to maintaining weight after treatment.

The continuous glucose monitor, typically associated with diabetes management, tracks glucose levels via a small sensor worn on the arm. This data connects wirelessly to the Signos app, where users can document their food intake and physical activity. The app employs this information to generate tailored recommendations, supporting users in developing healthy behaviors over the long term.

Beyond merely assisting with weight loss, the Signos system provides valuable insights into individual physiological responses to different foods and exercise routines. By empowering users to understand their bodies better, it encourages meaningful changes in behavior aimed at sustainable weight management.

While specific usage numbers remain undisclosed, Fouladgar-Mercer revealed that tens of thousands of individuals have previously engaged with the Signos system. Following FDA approval, the company has ramped up its resources to meet anticipated demand, preparing to support a wide audience eager for effective weight management solutions.